Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2020

View Archived Issues

Enrollment ongoing in phase II study of LX-9211 in postherpetic neuralgia

CDI-45205 selected as lead compound for development against coronaviruses

11C-PABA for dynamic PET to evaluate renal function: preclinical and first-in-human results

Safety and efficacy of once-weekly insulin icodec compared with once-daily glargine in phase II

First patients dosed in phase I/II study of SIIPL's COVID-19 vaccine candidate plus CpG-1018

Intranasal RECCE-327 and RECCE-529 demonstrate activity against SARS-CoV-2 virus in vivo

Topline data from pivotal phase II/III VALO study of Qtorin rapamycin in pachyonychia congenita

Indian researchers divulge new compounds for tuberculosis

University of Minnesota discloses BET inhibitors

Beijing Tide Pharmaceutical synthesizes new ATR kinase inhibitors

Shaanxi Panlong Pharmaceutical presents compounds for leukemia

Verseau Therapeutics describes new anti-SIGLEC9 antibodies

FDA approves international phase III study of carrimycin in patients with severe COVID-19

Health Canada authorizes Moderna's COVID-19 vaccine

FDA issues clinical hold on IND application for AdCOVID

A2 Biotherapeutics and Merck collaborate to develop novel allogeneic cell therapy

Adipocyte telomere length controls susceptibility to diabetes

First-in-human data presented for AMG-701 in relapsed/refractory multiple myeloma

FDA issues a Study May Proceed letter for phase Ib trial of CX-5461

Abionyx launches phase IIa study of CER-001 for prevention of AKI in septic patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...